Robert J. Kreitman, MD, of the National Cancer Institute, discusses findings on moxetumomab pasudotox in heavily pretreated patients with relapsed or refractory hairy cell leukemia (Abstract 7004).
Joseph A. Sparano, MD, of Montefiore Medical Center, discusses phase III study results on chemoendocrine treatment vs endocrine treatment alone in hormone receptor–positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score (Abstract LBA1).
Geertjan Van Tienhoven, MD, PhD, of the Dutch Pancreatic Cancer Group, discusses phase III study findings on preoperative chemoradiotherapy vs immediate surgery for resectable and borderline resectable pancreatic cancer (Abstract LBA4002).
Bruce E. Johnson, MD, of the Lowe Center for Thoracic Oncology and ASCO’s outgoing President, talks with Monica M. Bertagnolli, MD, of Brigham and Women’s Hospital and the incoming President, about what has been achieved in the past year and what lies ahead.
David F. McDermott, MD, of Beth Israel Deaconess Medical Center, discusses study findings on pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (Abstract 4500).
Tony Mok, MD, of the Chinese University of Hong Kong, discusses study findings on dacomitinib vs gefitinib for first-line treatment of advanced non–small cell lung cancer, a final overall survival analysis.
